Login to Your Account



Third Rock Start-up Sage Debuts with $35M Series A

By Catherine Shaffer


Tuesday, October 18, 2011
Third Rock Ventures LLC launched a new company, Sage Therapeutics, with a $35 million Series A financing to develop new therapies for schizophrenia, depression, pain and traumatic brain injury based on modulation of GABA and glutamate neurotransmitters.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription